Department of Life Sciences, University of Trieste, Trieste 34127, Italy.
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy.
World J Gastroenterol. 2021 Oct 14;27(38):6348-6356. doi: 10.3748/wjg.v27.i38.6348.
Thiopurines are immunomodulators used in the treatment of acute lymphoblastic leukemia and inflammatory bowel diseases. Adverse reactions to these agents are one of the main causes of treatment discontinuation or interruption. Myelosuppression is the most frequent adverse effect; however, approximately 5%-20% of patients develop gastrointestinal toxicity. The identification of biomarkers able to prevent and/or monitor these adverse reactions would be useful for clinicians for the proactive management of long-term thiopurine therapy. In this editorial, we discuss evidence supporting the use of , , and genes, in addition to and as possible biomarkers for thiopurine-related gastrointestinal toxicity.
硫嘌呤类药物是用于治疗急性淋巴细胞白血病和炎症性肠病的免疫调节剂。这些药物的不良反应是导致治疗停止或中断的主要原因之一。骨髓抑制是最常见的不良反应，但约 5%-20%的患者会出现胃肠道毒性。能够预防和/或监测这些不良反应的生物标志物的鉴定，对于临床医生主动管理长期硫嘌呤治疗将是有用的。在这篇社论中，我们讨论了支持使用、、和 基因，以及 和 作为硫嘌呤相关胃肠道毒性的可能生物标志物的证据。
